Sartorius, c-LEcta sign distribution contract for Serratia marcescens nuclease

As a part of the agreement, Sartorius will market the endonuclease, used in a range of biopharmaceutical production processes, as Denarase.

Sartorius Stedim purification technologies vice president Uwe Gottschalk said, "This endonuclease provides outstanding advantages from which our customers will benefit directly, such as cost efficiency and high performance."

c-LEcta has used genetically engineered Bacillus strain in optimizing the production process for Serratia marcescens nuclease to increase the yield of enzyme activity and remove endotoxins.

c-LEcta managing director Marc Struhalla said, "The technology developed by c-LEcta allows us to provide nuclease to our customers in the highest quality."